Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

NCT04718038 · clinicaltrials.gov ↗

COMPLETED

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab combind mFOLFOX6/FOLFIRI

Sponsor

Henan Cancer Hospital